The benefits of nicotine on brain function have been discussed in the media occasionally but rarely given much of a spotlight. The link between nicotine intake and a lower risk of getting Alzheimer’s has been established scientifically and published by mainstream sources such as The Daily Mail and others.
But Now There is a Drug Made From Nicotine … And it’s Being Used to Treat Ebola!
According to an article at ConservativeByte.com:
Dr. Kent Brantly, who is being treated with an experimental drug for the Ebola virus at Atlanta’s Emory University Hospital, will soon be joined by the second American to have contracted the virus.
The drug ZMapp, made by Mapp Biopharmaceutical Inc., of San Diego, has been identified as a potential treatment for the disease but had never been tested on a human until now. The second patient, Nancy Writebol, who left for Atlanta from Monrovia, Liberia, on Tuesday, has started recovering from the disease after receiving two doses of the drug before leaving for the U.S., according to the Associated Press, or AP. ZMapp was developed by a long-running research program supported by the U.S. government and its military.
ZMapp is made out of nicotine leaves and was tested on mice having the virus, of which 80 percent survived.
On the Zmapp’s Wikipedia page President Obama is quoted as not yet being ready to verify whether this experimental drug is effective or not:
At an August 6, 2014 press conference, Barack Obama, the president of the United States, was questioned regarding whether the cocktail should be fast-tracked for approval or be made available to sick patients outside of the United States. He responded, “I think we’ve got to let the science guide us. I don’t think all the information’s in on whether this drug is helpful.”
We’ll keep you updated with this story as it progresses.